Newsletters
Read our latest newsletters here and keep up to date with what we’ve been up to.
Isogenica Launches A New Library Boosting Outputs For Vhh Antibody Discovery
Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.
Isogenica Vhh Bi And Multispecific Plugandplay Platform
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.
Upcoming Nature Webinar: VHH as building blocks for immune and tumour cell-targeting
Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.
Isogenica Is Attending Bio Digital 2021
Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.
Using Llama-vhh To Optimize T-cell Mediated Immunotherapies
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.
Dr Bjorn Cochlovius appointed as Chairman of Isogenica Board of Directors
Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019.
